NASDAQ:WINT   Windtree Therapeutics, Inc.

WINT - nov 26 :

Wind-tree Is Studying Istaroxime in Early Cardiogenic Shock Patients

WARRINGTON, Pa., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced the results of U.S. hospital claims data analysis showing hospital inpatient mortality and length of hospital stay for cardiogenic shock patients.

Cardiogenic shock is a serious condition that occurs when the heart cannot pump enough blood and oxygen to the brain, kidneys, and other vital organs. Cardiogenic shock is a medical emergency and needs to be treated immediately.1 There is a lack of satisfactory pharmacological intervention to reverse the conditions as available therapies have unwanted side effects such as risk for arrhythmias, decreasing blood pressure, renal dysfunction and even increases in mortality that limit their usefulness and position them as “rescue medicines” for severe cases.

U.S. hospital claims data reveals that inpatient mortality for cardiogenic shock patients was 30% in 2020.2 To help explain the relative severity of cardiogenic shock, the acute myocardial infarction (e.g. “heart attack”) mortality rate in the U.S. was 5% in 2020.3 The analysis, along with previously reported primary market research with 100 U.S. cardiologists noting a high need for new therapies and their high likelihood of using an agent with istaroxime’s observed clinical profile further reveals the need for improved pharmacologic innovation for cardiogenic shock patients.

Additionally, U.S. hospital claims data was assessed to determine length of stay in the hospital for cardiogenic shock patients. The average length of stay for patients with cardiogenic shock was 19.6 days with a median of 10 days in 2020.4 According to the Agency for Healthcare Research and Quality (AHRQ), the U.S. national average for a hospital stay of any disease was 4.6 days in 2020.5